Marker Therapeutics, Inc. (NASDAQ:MRKR) Sees Significant Increase in Short Interest

Marker Therapeutics, Inc. (NASDAQ:MRKR) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 335,196 shares, a growth of 43.5% from the November 30th total of 233,661 shares. Based on an average daily volume of 311,655 shares, the days-to-cover ratio is currently 1.1 days. Approximately 2.2% of the shares of the company are sold short. Approximately 2.2% of the shares of the company are sold short. Based on an average daily volume of 311,655 shares, the days-to-cover ratio is currently 1.1 days.

Hedge Funds Weigh In On Marker Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new stake in shares of Marker Therapeutics during the 2nd quarter worth $33,000. Two Sigma Investments LP acquired a new position in Marker Therapeutics during the third quarter worth about $33,000. Finally, Virtu Financial LLC bought a new position in shares of Marker Therapeutics in the third quarter worth about $25,000. Institutional investors own 22.39% of the company’s stock.

Marker Therapeutics Trading Down 3.3%

Marker Therapeutics stock traded down $0.05 during trading hours on Tuesday, reaching $1.47. 208,290 shares of the stock were exchanged, compared to its average volume of 282,612. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $4.07. The stock has a 50 day moving average of $1.16 and a two-hundred day moving average of $1.21.

Marker Therapeutics (NASDAQ:MRKR) last issued its earnings results on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.57. The company had revenue of $1.23 million during the quarter, compared to analysts’ expectations of $0.72 million. Marker Therapeutics had a negative net margin of 304.56% and a negative return on equity of 92.35%. On average, analysts forecast that Marker Therapeutics will post -0.65 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MRKR has been the subject of several recent research reports. HC Wainwright initiated coverage on Marker Therapeutics in a research note on Monday, December 8th. They issued a “buy” rating and a $10.00 price target for the company. Wall Street Zen downgraded Marker Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. Zacks Research raised shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, November 18th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Marker Therapeutics in a research report on Monday, December 22nd. Finally, UBS Group reiterated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. Three research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $10.17.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.